Home

Leonardoda dátum hangosan overall survival bemondó Szivárvány Csíkos

ADMIRAL Trial: XOSPATA® (gilteritinib) Overall Survival
ADMIRAL Trial: XOSPATA® (gilteritinib) Overall Survival

Overall survival and objective response in advanced unresectable  hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of  Hepatology
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology

The prognostic impact of RAS on overall survival following liver resection  in early versus late-onset colorectal cancer patients | British Journal of  Cancer
The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients | British Journal of Cancer

Metastatic behavior and overall survival according to breast cancer  subtypes in stage IV inflammatory breast cancer | Breast Cancer Research |  Full Text
Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer | Breast Cancer Research | Full Text

Primary Myelofibrosis (MF) Disease | Jakafi HCP
Primary Myelofibrosis (MF) Disease | Jakafi HCP

A prognostic nomogram for overall survival in male breast cancer with  histology of infiltrating duct carcinoma after surgery [PeerJ]
A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ]

Nivolumab Boosted Survival in Relapsed Mesothelioma - ILCN.org (ILCN/WCLC)
Nivolumab Boosted Survival in Relapsed Mesothelioma - ILCN.org (ILCN/WCLC)

Overall survival of black and white men with metastatic  castration-resistant prostate cancer (mCRPC): a 20-year retrospective  analysis in the largest healthcare trust in England | Prostate Cancer and  Prostatic Diseases
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in  newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase  3 trial - The Lancet
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet

Overall survival of patients with EGFR mutation-positive non-small-cell  lung cancer treated with erlotinib, gefitinib or afatinib under drug  programmes in Poland – real-world data
Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data

Progression free survival rate at 9 and 18 weeks predict overall survival  in patients with malignant pleural mesothelioma: An individual patient  pooled analysis of 10 European Organisation for Research and Treatment of
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer |  NEJM
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM

Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and  Human Body Modeling 2020 - NCBI Bookshelf
Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and Human Body Modeling 2020 - NCBI Bookshelf

Cancers | Free Full-Text | Development of a Prognostic Model of Overall  Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men
Cancers | Free Full-Text | Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men

A prognostic model for overall survival of patients with early-stage  non-small cell lung cancer: a multicentre, retrospective study - The Lancet  Digital Health
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health

Event-free survival > Overall survival? - data analysis - Datamethods  Discussion Forum
Event-free survival > Overall survival? - data analysis - Datamethods Discussion Forum

Overall Survival Curve [IMAGE] | EurekAlert! Science News Releases
Overall Survival Curve [IMAGE] | EurekAlert! Science News Releases

図11 Overall Survival (Updated)
図11 Overall Survival (Updated)

TROPiCS-02 Results | TRODELVY® (sacituzumab govitecan-hziy) | Official HCP  Site
TROPiCS-02 Results | TRODELVY® (sacituzumab govitecan-hziy) | Official HCP Site

Overall Survival. Kaplan-Meier estimates of overall survival in... |  Download Scientific Diagram
Overall Survival. Kaplan-Meier estimates of overall survival in... | Download Scientific Diagram

Prediction of survival benefits from progression-free survival benefits in  advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334  patients from 5 randomised trials | BMJ Open
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open

Kaplan-Meier Plot of Overall Survival (ITT Population) | Download  Scientific Diagram
Kaplan-Meier Plot of Overall Survival (ITT Population) | Download Scientific Diagram

Long-term follow-up of overall survival for cabozantinib versus everolimus  in advanced renal cell carcinoma | British Journal of Cancer
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC  | NEJM
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM

IMFINZI® (durvalumab) Efficacy & Clinical Trials for 1L ES-SCLC
IMFINZI® (durvalumab) Efficacy & Clinical Trials for 1L ES-SCLC

VENCLEXTA® (venetoclax tablets) | VIALE-A Trial Overall Survival Data
VENCLEXTA® (venetoclax tablets) | VIALE-A Trial Overall Survival Data

BioCentury - The latest twist in the overall survival debate
BioCentury - The latest twist in the overall survival debate

Cancers | Free Full-Text | Novel Agents as Main Drivers for Continued  Improvement in Survival in Multiple Myeloma
Cancers | Free Full-Text | Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

LIBTAYO® (cemiplimab-rwlc) Overall Survival Rate in Advanced NSCLC
LIBTAYO® (cemiplimab-rwlc) Overall Survival Rate in Advanced NSCLC

Real-world time trends in overall survival, treatments and patient  characteristics in HR+/HER2− metastatic breast cancer: an observational  study of the SONABRE Registry - The Lancet Regional Health – Europe
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe